Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Obesity
Clinical trial register · United Kingdom · industry-sponsored

Obesity Trials in the UK, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 10 Bristol 10 Birmingham 9 Blackpool 8 Liverpool 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novo Nordisk A/S13 Eli Lilly and Company8 Amgen4 Boehringer Ingelheim3 Kailera2
Site city
London10 Bristol10 Birmingham9 Blackpool8 Liverpool7
All 96 cities
Target enrolment
to

Obesity trials in the UK

37 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Newquay, Poole, Thetford, West Bromwich, Chichester, West Kirby, Aberdeen, Ashton-under-Lyne
2026-10-26
Not yet open
Boehringer Ingelheim
Phase 3
600
Leicester
2026-10-23
Recruiting
Weight and Metabolic Management Study
NCT07789223Overweight, Obesity, Weight Maintenance
Elenzia
Not applicable
200
Redditch
2026-09-15
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Bellshill, Cardiff, Edgbaston, London, Manchester, Stoke-on-Trent, Warrington
2026-08-31
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Cardiff, Edgbaston, Glasgow, London, Manchester, Stoke-on-Trent, Warrington
2026-08-28
Recruiting
Amgen
Phase 3
950
Birmingham
2026-07-29
Active, closed
Boehringer Ingelheim
Phase 2
344
Blackpool, Guisborough, High Wycombe, Leicester, Middlesbrough, Oxford
2026-06-30
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Truro, Rhyl, Torquay, Dorchester, Airdrie, Tooting, Isleworth, Norwich
2026-05-11
Active, closed
Novo Nordisk A/S
Phase 3
606
Macclesfield, Rotherham, Soham, Wellingborough
2026-04-21
Recruiting
Boston Scientific Corporation
Observational
200
Coventry
2026-04-07
Recruiting
AstraZeneca
Phase 1
104
Harrow
2026-03-30
Active, closed
Boehringer Ingelheim
Phase 1
80
Nottingham
2026-03-11
Recruiting
Novo Nordisk A/S
Phase 3
1,150
Fowey, Poole, Macclesfield, Pickering, Addlestone, Bradford on Avon, Hounslow, Nantwich
2026-02-24
Active, closed
Pfizer
Phase 3
1,078
Hendon, Glasgow, Bellshill, Birmingham, Bristol, Bromborough, Edgbaston, Enfield
2026-02-24
Recruiting
Eli Lilly and Company
Phase 3
1,980
Blackpool, Bradford on Avon, Lancashire, Lancaster, Londonderry, Manchester, Peterborough, Romsey
2026-02-06
Recruiting
Novo Nordisk A/S
Phase 3
460
Birmingham, Liverpool, London
2026-01-08
Active, closed
Kailera
Phase 3
1,270
Exeter, Torquay, Weymouth, Glasgow, London, Leicester, Rotherham
2025-12-30
Active, closed
Kailera
Phase 3
2,530
Soham, Torpoint, Hull, Stevenage, Leicester, Nottingham, Newcastle upon Tyne, Bradford
2025-12-18
Recruiting
Eli Lilly and Company
Phase 4
3,000
Altrincham, Ashton-under-Lyne, Bolton, Bury, Cheshire, Great Lever, Hyde SK14, Manchester
2025-11-24
Active, closed
Eli Lilly and Company
Phase 3
250
Birmingham, Blackpool, Bradford on Avon, Bromborough, Cheadle, Hounslow, Oxford, Penzance
2025-11-17
Active, closed
Novo Nordisk A/S
Phase 3
300
Liskeard, Newquay, Torquay
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
330
Liskeard, Newquay, Torquay, Bushey, London
2025-11-05
Recruiting
Amgen
Phase 3
12,800
Birmingham, Blackpool, Bristol, Cambridge, Chester, Coventry, Dudley, Dundee
2025-07-25
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Airdrie, Ashington, Belfast, Bournemouth, Bridgend, Bristol, Chichester, Dundee
2025-06-25
Active, closed
Hoffmann-La Roche
Phase 2
285
Blackpool, Leicester, Shipley, Coventry, Northwood, Orpington
2025-05-05
By invitation
Novo Nordisk A/S
Observational
1,250
West Bromwich, Barnsley, Hull, London, Luton, Tooting
2025-05-01
Active, closed
Amgen
Phase 3
3,853
Belfast, Birmingham, Blackpool, Bristol, Cornwall, Ely, Glasgow, Hull
2025-03-12
Active, closed
Eli Lilly and Company
Phase 3
643
Birmingham, Blackburn, Blackpool, Bradford on Avon, Bromborough, Cheadle, Hounslow, Oxford
2025-03-05
Active, closed
Novo Nordisk A/S
Phase 3
400
Bristol, Cambridge, Coventry, Liverpool, London, Swansea, Taunton
2025-02-10
Recruiting
Eli Lilly and Company
Phase 3
125
Barnsley, Bristol, Cambridge, Dundee, Harrow, Hull, Liverpool
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
150
Barnsley, Dundee, Hull
2024-11-18
Active, closed
Novo Nordisk A/S
Phase 4
500
Birmingham, Bristol, Leeds, Liverpool, London, Sheffield, Southampton
2024-09-17
Recruiting
Eli Lilly and Company
Phase 3
300
Cambridge, Glagow, Leeds, Leicester, Liverpool, London, Newcastle upon Tyne, Sheffield
2024-06-03
Active, closed
Novo Nordisk A/S
Phase 3
212
Birmingham, Bristol, Leeds, Liverpool, Southampton
2023-07-07
By invitation
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
NCT05872022Pregnancy, Obesity, Overweight
Novo Nordisk A/S
Observational
728
London
2023-07-05
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Orpington, Blackpool, Bristol, Cambridge, Chester, Chippenham, Coventry, Liverpool
2022-11-01
Active, closed
Eli Lilly and Company
Phase 3
15,374
Blackburn, Bristol, Coventry, Dundee, Ely, Fowey, Hull, Ipswich
2022-10-11
Rows per page Showing 1–37 of 37
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-uk/condition/obesity

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 10 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 37 of those studies listing the condition Obesity.

How many Obesity trials are recruiting in the UK?

16 of the 37 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:15 UTC sync. A further 2 have not yet opened recruitment, 17 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Obesity), 37 studies
PhaseStudiesRecruitingShare
Phase 3271273%
Observational318.1%
Phase 1215.4%
Phase 2205.4%
Phase 4215.4%
Not applicable112.7%

Most active sponsors

Lead sponsors with the most studies (Obesity)
Lead sponsorStudiesRecruiting
Novo Nordisk A/S133
Eli Lilly and Company85
Amgen43
Boehringer Ingelheim30
Ascletis Pharma (China) Co., Limited22
Kailera20
AstraZeneca11
Boston Scientific Corporation11
Elenzia11
Hoffmann-La Roche10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.